Navigation Links
Stanford scientists develop gene therapy approach to grow blood vessels in ischemic limbs
Date:3/6/2012

Bethesda, MDA new research discovery by a team of Stanford and European scientists offers hope that people with atherosclerotic disease may one day be able to avoid limb amputation related to ischemia. A new research report appearing online in the FASEB Journal suggests that the delivery of genes for two molecules naturally produced by the body, called "PDGF-BB" and "VEGF" may successfully cause the body to grow new blood vessels that can save ischemic limbs.

"We hope that our findings will ultimately develop into a safe and effective therapy for the many patients, suffering from blocked arteries in the limbs, who are currently not adequately treated by surgery or drugs," said Helen M. Blau, Ph.D., a senior researcher involved in the work and Associate Editor of the FASEB Journal from the Baxter Laboratory for Stem Cell Biology at the Institute for Regenerative Medicine and Stem Cell Biology at Stanford. "This could help avoid the devastating consequences of limb amputations for both patients and their families."

To make this discovery, Blau and colleagues, including Andrea Banfi (now at Basel University), introduced the genes for PDGF-BB and VEGF into the muscles of mice, either independently or together. When high doses of VEGF alone were produced, they caused the growth of vascular tumors. When the two factors were produced in unbalanced amounts, tumor growth also occurred. When VEGF and PDGF were delivered in a fixed ratio relative to one another, however, no tumors occurred, and blood flow was restored to ischemic muscle tissue and damage repaired without any toxic effects. To achieve a "balanced" delivery of PDGF-BB and VEGF, scientists placed both genes in a single gene therapy delivery mechanism, called a "vector."

Although the report shows the feasibility of growing robust and safe new blood vessels that restore blood flow to diseased tissues, Blau points out that "there are multiple challenges to correcting peripheral vasculature disease by using proangiogenic gene therapy strategies. Two important challenges are what to deliver and how to get it to where it can have beneficial effects. Clinical success will require both delivering a gene therapy construct that encodes for effective angiogenic factors and ensuring that the sites of delivery are where the construct can have the greatest clinical benefit."

"This ingenious work, based on the latest techniques of molecular biology, tells us that it is possible to reinvigorate parts of our body that can't get enough blood to keep them going," said Gerald Weissmann, M.D., Editor-in-Chief of the FASEB Journal. "The next question is whether this approach will work in humans and exactly how to deliver the new treatment to places that need it the most."


'/>"/>

Contact: Cody Mooneyhan
cmooneyhan@faseb.org
301-634-7104
Federation of American Societies for Experimental Biology
Source:Eurekalert

Related biology news :

1. Stanford scientist to discuss the challenges and opportunities of carbon sequestration at AAAS
2. JoVE partners with Stanford University for Medicine X Conference
3. AGU meeting: Stanford scientists subject rocks to hellish conditions to combat global warming
4. Squid mystery in Mexican waters unraveled by Stanford biologist and a class of students
5. OpenSim open-source software from Stanford accurately models human motion
6. Gene variation predicts rate of age-related decline in mental performance, Stanford study
7. Stanford researchers examine impact of green politics on recent national elections
8. Stanford Precourt Institute and TomKat Center award energy research grants
9. Dual-action protein developed at Stanford better restricts blood vessel formation
10. Stanford engineers redefine how the brain plans movement
11. Global warming could alter the US premium wine industry in 30 years, says Stanford study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/11/2017)... 11, 2017 Crossmatch®, a globally-recognized leader ... today announced that it has been awarded a ... Activity (IARPA) to develop next-generation Presentation Attack Detection ... "Innovation has been a driving force within Crossmatch ... allow us to innovate and develop new technologies ...
(Date:4/6/2017)... Forecasts by Product Type (EAC), ... End-Use (Transportation & Logistics, Government & Public Sector, Utilities ... Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), ... you looking for a definitive report on the $27.9bn ... ...
(Date:4/4/2017)... NEW YORK , April 4, 2017   ... solutions, today announced that the United States Patent and ... The patent broadly covers the linking of an iris ... the same transaction) and represents the company,s 45 th ... our latest patent is very timely given the multi-modal ...
Breaking Biology News(10 mins):
(Date:9/22/2017)... Springfield, Mo. (PRWEB) , ... September 22, 2017 ... ... company, recently announced it will host a booth at premier packaging event PACK ... is hosted by the Packaging Machinery Manufacturers Institute (PMMI). , At this year’s ...
(Date:9/21/2017)... ... September 21, 2017 , ... Dr. Greg Leyer, Chief Scientific Officer of UAS ... His presentation is at 12:10pm in the Probiotics Resource Center, Mandalay Bay Expo Hall. ... and discuss how probiotics have shown impressive data in areas outside the gut including ...
(Date:9/21/2017)... ... 2017 , ... When a downtown Greenville portion of the ... efficient thanks to the continuing efforts of members of the Reedy River Water ... stakeholders, including officials from area counties and cities, Renewable Water Resources (ReWa), community ...
(Date:9/20/2017)... ... 2017 , ... Diversity focused business accelerator, The Refinery , announced today ... uncover the top technology-driven, women-led startups in Boston, MA, New Haven/Hamden, CT, and Newark, ... events going on that week – in Boston, it will be part of the ...
Breaking Biology Technology: